Pharma Journalist -

Hutchison China MediTech Limited and BeiGene, Ltd. announced that they have entered into a clinical collaboration agreement to evaluate the safety, tolerability and efficacy of…
Read More...

Merck, known as MSD outside the United States and Canada, and Themis, a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer, today announced…
Read More...

Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people…
Read More...

Novasep and Lysogene announced the signature of an agreement for the development and manufacturing of LYS-GM101, an AAVrh10-based gene therapy drug candidate for the treatment of GM1…
Read More...

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics LP, a closely held biotechnology company, announced that the companies have entered into a…
Read More...

Repare Therapeutics Inc. (“Repare”), a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in…
Read More...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for children aged 6 to 11 years with…
Read More...

Merck, known as MSD outside the United States and Canada, and IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges,…
Read More...

ArcherDX, Inc. announced a strategic collaboration with AstraZeneca to develop assays to support multiple planned Phase 3 clinical trials for AstraZeneca’s targeted immuno-oncology…
Read More...

ONCODESIGN and HITGEN announced the start of a worldwide strategic alliance in Integrated Drug Discovery Services for the identification and progression of new chemical entities,…
Read More...